Surgeon-modified stent grafts for aortic aneurysms near the kidneys and chest
Tests surgeon-modified endografts in adults with pararenal or thoracoabdominal aortic aneurysm unsuitable for open surgery.
Key facts
- Who runs it
- Konstantinos Arnaoutakis, MD
- Where
- Wesley Chapel, United StatesSee the site
- Trial code
- Registry title
- PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 6 Jun 2023
- Expected to end
- Feb 2030
- Type of study
- Interventional
- Treatments tested
- PMEG
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a pararenal or thoracoabdominal aortic aneurysm (a bulge in the main artery near the kidneys or chest and belly). They cannot have open surgery because of other health problems. Their anatomy does not allow standard ready-made stent grafts.
- Age
- 18 years or older
- Sex
- Male or female
- Disease stage
- Aneurysm of the thoracoabdominal or pararenal aorta, with or without chronic dissection. A standard graft would need to cover the celiac, SMA and/or renal arteries. Expected survival beyond 1 year after repair.
Main reasons for not taking part
- Can be treated with a marketed stent graft, including a factory-made custom device, or can join a manufacturer study
- Ruptured aneurysm with unstable blood pressure or circulation
- Severe heart failure, unstable angina, or stroke or heart attack within 3 months
- eGFR below 30ml/min, unless on or starting dialysis
- Pregnancy or breastfeeding, or active body-wide infection
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Male or female, aged ≥18 years
- Expected survival beyond 1 year following successful aneurysm repair
- Anatomy that would require coverage of the celiac artery, superior mesenteric artery (SMA), and/or renal arteries if conventional, FDA-approved endograft were implanted to obtain adequate sealing zone length
- Aneurysm of the thoracoabdominal or pararenal aorta with or without chronic dissection
- Adequate proximal zone of fixation
- Adequate distal zone of fixation
- No more than 5 non-aneurysmal visceral (celiac, SMA, or renal) arteries with diameters between 4-12mm
- Adequate arterial access for delivery system; use of iliac conduit is permitted as necessary
Who cannot take part
- Pregnancy or lactation (confirmed per standard of care surgical practice)
- Major, unrelated surgical procedure planned ≤30 days from endovascular repair
- Patient is ≤30 days beyond primary endpoint for another investigative clinical drug/device trial
- Unstable angina
- Stroke or MI within 3 months of planned treatment date
- Active systemic infection and/or mycotic aneurysm
- Uncorrectable coagulopathy or other bleeding diathesis
- Known allergy to device material or contrast material that cannot be adequately pre-medicated
- Baseline eGFR < 30ml/min, unless currently on or to be initiating dialysis
- Moderate-to-severe aortic neck calcification, thrombus, or tortuosity
- Severe iliac stenosis, calcification, or tortuosity with no ability to perform a conduit
- Proximal landing within zone 0 or 1
- Inability to maintain at least one patent hypogastric artery
- Freely ruptured aneurysm with hemodynamic instability
- Non-ambulatory status
- Severe CHF
- Body habitus that would preclude adequate fluoroscopic visualization of aorta
- Social or psychological issues that would interfere with ability to comply with all study procedures for the duration of the study
- Can be treated in accordance with the instructions for use with a legally marketed endovascular device, including a manufacturer-fabricated custom device
- Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution
Where in United States
- Orlando Health Wiregrass Ranch HospitalWesley Chapel, United StatesContact: TIna HendersonTaking people
About the trial
What the trial wants to find out
The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.
The group in the trial
- Physician-modified endograftsTreatment being tested
For this clinical protocol, endografts which are commercially available will be modified in a sterile fashion on a back-table in the operating room.
Treatment: PMEG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Spinal Cord Ischemia and Mortality and Morbidity After Endovascular Repair of Pararenal and Thoracoabdominal Aortic Aneurysm Using Surgeon-Modified Endografts
- Plain-language title
- Surgeon-modified stent grafts for aortic aneurysms near the kidneys and chestGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Differences in aortic remodeling in patients with type 1a and type 5 endoleak who undergo salvage with fenestrated/branched endovascular aortic repair.Journal of vascular surgery, 2025
- Comparative outcomes of physician-modified fenestrated/branched endovascular aortic aneurysm repair in the setting of prior failed endovascular aneurysm repair.Journal of vascular surgery, 2023
- Record updated
- 16 October 2026